Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.
While the effects of single growth factors on endothelial cells (ECs) have been extensively studied, the importance of induction of growth factors such as PDGF-BB (platelet derived growth factor) in ECs and its impact on tumor cell functions are only partly understood. Human umbilical vein endothelial cells (HUVECs) were cultured under serum-free conditions and stimulated by 20 ng/ml VEGF (vascular endothelial growth factor) or 20 ng/ml bFGF (basic fibroblastic growth factor). As determined by real-time PCR, both VEGF and bFGF induced a significant (up to 4-fold) increase in PDGF-B RNA expression which was time- and dose-dependent (p<0.05). Similarly, conditioned medium (CM) from lung cancer cells (A549) which is known to contain multiple growth factors including VEGF and bFGF also induced PDGF-B RNA expression. Using ELISA assays, VEGF and bFGF significantly increased PDGF-BB protein secretion in HUVECs (p<0.01). By addition of BIBF 1000, a novel inhibitor of the VEGF and bFGF receptor kinases, the effect of VEGF on PDGF-B RNA induction was significantly antagonized (p<0.01). Furthermore, we studied the biological significance of EC-derived PDGF-BB on lung cancer cells. Interestingly, HUVEC-derived CM significantly stimulated migration of A549 cells (p<0.001) with a trend to further increased migration with the use of VEGF-stimulated (PDGF-BB rich) CM (p=0.2). Collectively, endothelial and lung cancer cells seem to interact via various paracrine pathways, e.g. by the reciprocal induction of VEGF and PDGF-BB. Thus, targeting key molecules would result in expression alterations of multiple factors and alter the biological functions of both stromal and tumor cells.
Department of Internal Medicine-Thoracic Oncology, Clinic for Thoracic Diseases, University of Heidelberg, Heidelberg, Germany. niels.reinmuth@thoraxklinik-heidelberg.de
Niels
N
Reinmuth
Sonja
S
Rensinghoff
Miriam
M
Raedel
Nicole
N
Fehrmann
Christian
C
Schwöppe
Torsten
T
Kessler
Guido
G
Bisping
Frank
F
Hilberg
Gerald J
GJ
Roth
Wolfgang
W
Berdel
Michael
M
Thomas
Rolf M
RM
Mesters
D001331:Automation; D000077214:Becaplermin; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008175:Lung Neoplasms / Q000378:metabolism*; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D020574:Proto-Oncogene Proteins c-sis; D012313:RNA / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
C509119:BIBF 1000; D007211:Indoles; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D000077214:Becaplermin; D012313:RNA